News Sentiment

LENZ sentiment intelligence

LENZ Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.59 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-5.1% over one week, -17.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -5.1% Price reacting lower
Trend fit Trend inactive -17.4% over four weeks
Fair value -73.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 39
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
simplywall.st 7
TradingView 6
LENZ Therapeutics 4
Stock Titan 4
Quiver Quantitative 3
www.marketscreener.com 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 21
Deals and strategy 6
Analyst action 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 65
TradingKey Direct company coverage

LENZ Therapeutics Inc (LENZ) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of LENZ Therapeutics Inc (LENZ), stating its current valuation score is 6.79, ranking it 297 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio is -1.74, significantly below its recent high

Tone
Negative 42/100
Event
Market update
Published
18 Jun 2026 05:40
Source
TradingKey
TradingKey Direct company coverage

LENZ Therapeutics Inc (LENZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of LENZ Therapeutics Inc (LENZ), focusing on its support and resistance levels, key indicators, and moving averages. The stock's current price momentum score is 6.40, ranking it 263 out of 388 in its industry, and it is trading between a

Tone
Negative 28/100
Event
Market update
Published
18 Jun 2026 05:40
Source
TradingKey